Literature DB >> 35867748

The ZCCHC14/TENT4 complex is required for hepatitis A virus RNA synthesis.

You Li1,2, Ichiro Misumi1,3, Tomoyuki Shiota1, Lu Sun1, Erik M Lenarcic4, Hyejeong Kim4, Takayoshi Shirasaki1, Adriana Hertel-Wulff1, Taylor Tibbs3,4, Joseph E Mitchell3,4, Kevin L McKnight1, Craig E Cameron1,4, Nathaniel J Moorman1,4, David R McGivern1,2, John M Cullen5, Jason K Whitmire1,3,4, Stanley M Lemon1,2,4.   

Abstract

Despite excellent vaccines, resurgent outbreaks of hepatitis A have caused thousands of hospitalizations and hundreds of deaths within the United States in recent years. There is no effective antiviral therapy for hepatitis A, and many aspects of the hepatitis A virus (HAV) replication cycle remain to be elucidated. Replication requires the zinc finger protein ZCCHC14 and noncanonical TENT4 poly(A) polymerases with which it associates, but the underlying mechanism is unknown. Here, we show that ZCCHC14 and TENT4A/B are required for viral RNA synthesis following translation of the viral genome in infected cells. Cross-linking immunoprecipitation sequencing (CLIP-seq) experiments revealed that ZCCHC14 binds a small stem-loop in the HAV 5' untranslated RNA possessing a Smaug recognition-like pentaloop to which it recruits TENT4. TENT4 polymerases lengthen and stabilize the 3' poly(A) tails of some cellular and viral mRNAs, but the chemical inhibition of TENT4A/B with the dihydroquinolizinone RG7834 had no impact on the length of the HAV 3' poly(A) tail, stability of HAV RNA, or cap-independent translation of the viral genome. By contrast, RG7834 inhibited the incorporation of 5-ethynyl uridine into nascent HAV RNA, indicating that TENT4A/B function in viral RNA synthesis. Consistent with potent in vitro antiviral activity against HAV (IC50 6.11 nM), orally administered RG7834 completely blocked HAV infection in Ifnar1-/- mice, and sharply reduced serum alanine aminotransferase activities, hepatocyte apoptosis, and intrahepatic inflammatory cell infiltrates in mice with acute hepatitis A. These results reveal requirements for ZCCHC14-TENT4A/B in hepatovirus RNA synthesis, and suggest that TENT4A/B inhibitors may be useful for preventing or treating hepatitis A in humans.

Entities:  

Keywords:  RNA-binding protein; animal model; antiviral therapy; hepatitis A; picornavirus

Mesh:

Substances:

Year:  2022        PMID: 35867748      PMCID: PMC9282228          DOI: 10.1073/pnas.2204511119

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  47 in total

1.  Mixed tailing by TENT4A and TENT4B shields mRNA from rapid deadenylation.

Authors:  Jaechul Lim; Dongwan Kim; Young-Suk Lee; Minju Ha; Mihye Lee; Jinah Yeo; Hyeshik Chang; Jaewon Song; Kwangseog Ahn; V Narry Kim
Journal:  Science       Date:  2018-07-19       Impact factor: 47.728

2.  Protein composition of the hepatitis A virus quasi-envelope.

Authors:  Kevin L McKnight; Ling Xie; Olga González-López; Efraín E Rivera-Serrano; Xian Chen; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-10       Impact factor: 11.205

3.  Replication of subgenomic hepatitis A virus RNAs expressing firefly luciferase is enhanced by mutations associated with adaptation of virus to growth in cultured cells.

Authors:  MinKyung Yi; Stanley M Lemon
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

4.  The RNA-binding SAM domain of Smaug defines a new family of post-transcriptional regulators.

Authors:  Tzvi Aviv; Zhen Lin; Stefanie Lau; Laura M Rendl; Frank Sicheri; Craig A Smibert
Journal:  Nat Struct Biol       Date:  2003-08

5.  The Dihydroquinolizinone Compound RG7834 Inhibits the Polyadenylase Function of PAPD5 and PAPD7 and Accelerates the Degradation of Matured Hepatitis B Virus Surface Protein mRNA.

Authors:  Liren Sun; Fang Zhang; Fang Guo; Fei Liu; Jessie Kulsuptrakul; Andreas Puschnik; Min Gao; Rene Rijnbrand; Michael Sofia; Timothy Block; Tianlun Zhou
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 6.  Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention.

Authors:  Stanley M Lemon; Jördis J Ott; Pierre Van Damme; Daniel Shouval
Journal:  J Hepatol       Date:  2017-09-05       Impact factor: 25.083

7.  Robust transcriptome-wide discovery of RNA-binding protein binding sites with enhanced CLIP (eCLIP).

Authors:  Eric L Van Nostrand; Gabriel A Pratt; Alexander A Shishkin; Chelsea Gelboin-Burkhart; Mark Y Fang; Balaji Sundararaman; Steven M Blue; Thai B Nguyen; Christine Surka; Keri Elkins; Rebecca Stanton; Frank Rigo; Mitchell Guttman; Gene W Yeo
Journal:  Nat Methods       Date:  2016-03-28       Impact factor: 28.547

8.  Factors Associated With Hepatitis A Mortality During Person-to-Person Outbreaks: A Matched Case-Control Study-United States, 2016-2019.

Authors:  Megan G Hofmeister; Jian Xing; Monique A Foster; Ryan J Augustine; Cole Burkholder; Jim Collins; Shannon McBee; Erica D Thomasson; Douglas Thoroughman; Mark K Weng; Philip R Spradling
Journal:  Hepatology       Date:  2021-04-19       Impact factor: 17.425

9.  Hepatoselective Dihydroquinolizinone Bis-acids for HBsAg mRNA Degradation.

Authors:  Nicky Hwang; Liren Sun; Daisy Noe; Patrick Y S Lam; Tianlun Zhou; Timothy M Block; Yanming Du
Journal:  ACS Med Chem Lett       Date:  2021-06-22       Impact factor: 4.632

10.  Tissue-Dependent Expression and Translation of Circular RNAs with Recombinant AAV Vectors In Vivo.

Authors:  Rita M Meganck; Erin K Borchardt; Ruth M Castellanos Rivera; Miranda L Scalabrino; Jeremy E Wilusz; William F Marzluff; Aravind Asokan
Journal:  Mol Ther Nucleic Acids       Date:  2018-08-18       Impact factor: 8.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.